Elizaria®

BIOLOGICAL3 trials

Sponsors

AO GENERIUM

Conditions

Atypical Hemolytic Uremic SyndromeMarchiafava-Micheli SyndromeParoxysmal HemoglobinuriaParoxysmal Nocturnal HemoglobinuriaaHUS

Phase 3

Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH

CompletedNCT04463056

AO GENERIUMMarchiafava-Micheli Syndrome, Paroxysmal Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria

Start: 2017-11-29End: 2018-10-16Updated: 2021-09-01

Unknown Phase

Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®

CompletedNCT04671810

AO GENERIUMParoxysmal Nocturnal Hemoglobinuria

Start: 2019-06-13End: 2023-05-05Updated: 2023-09-13

Observational Study of Elizaria® in aHUS Patients

CompletedNCT04749810

AO GENERIUMaHUS, Atypical Hemolytic Uremic Syndrome

Start: 2019-12-19End: 2022-04-30Updated: 2022-08-04

Related Papers

Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab

Annals of Hematology2021-08-1630 citations